Works Cited

1. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ. 2004;171(1):51-58.

2. Kaye KS, Fraimow HS, Abrutyn E. Pathogens resistant to antimicrobial agents: epidemiology, molecular mechanisms, and clinical management. Infect Dis Clinics North Am. 2000;14(2):293-319.

3. Neu HC. Overview of mechanisms of bacterial resistance. Diagn Microbiol Infect Dis. 1989;12(4 suppl):S109-S116.

4. Normark BH, Normark S. Evolution and spread of antibiotic resistance. J Intern Med. 2002;252(2):91-106.

5. Raymond DP, Kuehnert MJ, Sawyer RG. CDC/SIS position paper: preventing antimicrobial-resistant bacterial infections in surgical patients. Surg Inf. 2002;3(4):375-385.

6. Tomasz A. The mechanism of the irreversible antimicrobial effects of penicillins: how the beta-lactam antibiotics kill and lyse bacteria. Annu Rev Microbiol. 1979;33:113.

7. Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev. 1995;8(4):557-584.

8. Georgopapadakou NH. Penicillin-binding proteins and bacterial resistance to beta-lactams. AntiMicrob Agents Chemother. 1993;37(10):2045-2053.

9. Nathwani D, Wood MJ. Penicillins: a current review of their clinical pharmacology and therapeutic use. Drugs. 1993;45(6):866-894.

10. Bush LM, Johnson CC. Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations. Infect Dis Clin North Am. 2000;14(2):409-433.

11. Richards ML, Prince RA, Kenaley KA, et al. Antimicrobial penetration into cerebrospinal fluid. Drug Intell Clin Pharm. 1981;15(5):341-368.

12. Tan JS, File TM Jr. Antipseudomonal penicillins. Med Clin North Am. 1995;79(4):679-693.

13. Watson ID, Boulton-Jones M, Stewart MJ, Henderson I, Payton CD. Pharmacokinetics of clavulanic acid-potentiated ticarcillin in renal failure. Ther Drug Monit. 1987;9(2):139-147.

14. Lin RY. A perspective on penicillin allergy. Arch Intern Med. 1992;152(5):930-937.

15. Babiak LM, Rybak MJ. Hematological effects associated with beta-lactam use. Drug Intell Clin Pharm. 1986;20(11):833-836.

16. Lacey CS. Interaction of dicloxacillin with warfarin. Ann Pharmacother. 2004;38(5):898.

17. Campbell BA, Cox SM. The penicillins. Obstet Gynecol Clin North Am. 1992;19(3):435-447.

18. Nau H. Clinical pharmacokinetics in pregnancy and perinatology. II. Penicillins. Dev Pharmacol Ther. 1987;10(3):174-198.

19. Kees F, Grobecker H. Systematics of beta-lactams: chemical properties and structure activity relationship of oral cephalosporins. Antibiot Chemother. 1995;47:1-7.

20. Fontana R, Cornaglia G, Ligozzi M, Mazzariol A. The final goal: penicillin-binding proteins and the target of cephalosporins.Clin Microbiol Infect. 2000;6(suppl 3):34-40.

21. Wise R. The pharmacokinetics of the oral cephalosporins—a review. J Antimicrob Chemother. 1990;26(suppl E):13-20.

22. Koch AL. Penicillin binding proteins, beta-lactams, and lactamases: offensives, attacks, and defensive countermeasures. Crit Rev Microbiol. 2000;26(4):205-220.

23. Hopkins JM, Towner KJ. Enhanced resistance to cefotaxime and imipenem associated with outer membrane protein alterations in Enterobacter aerogenes. J Antimicrob Chemother. 1990;25(1):49-55.

24. Gootz TD. Global dissemination of beta-lactamases mediating resistance to cephalosporins and carbapenems. Expert Rev Anti Infect Ther. 2004;2(2):317-327.

25. Neu HC. Pathophysiologic basis for the use of third-generation cephalosporins. Am J Med. 1990;88(suppl 4A):3S-11S.

26. Mazzei T, Dentico P. The pharmacokinetics of oral cephalosporins. Clin Microbiol Infect. 2000;6(suppl 3):53-54.

27. Borin MT. A review of the pharmacokinetics of cefpodoxime proxetil. Drugs. 1991;42(suppl 3):13-21.

28. Cherubin CE, Eng RH, Norrby R, et al. Penetration of newer cephalosporins into cerebrospinal fluid. Rev Infect Dis. 1989;11(4):526-548.

29. Balant LP, Dayer P, Fabre J. Consequences of renal insufficiency on the hepatic clearance of some drugs. Int J Clin Pharmacol Res. 1983;3(6):459-474.

30. Norrby SR. Side effects of cephalosporins. Drugs. 1987;34(suppl 2):105-120.

31. Tune BM. Renal tubular transport and nephrotoxicity of beta lactam antibiotics: structure-activity relationships. Miner Electrolyte Metab. 1994;20(4):221-231.

32. Famularo G, Polchi S, De Simone C. Acute cholecystitis and pancreatitis in a patient with biliary sludge associated with the use of ceftriazone: a rare but potentially severe complication. Ann Ital Med Int. 1999;14(3):202-204.

33. Alanis A, Weinstein AJ. Adverse reactions associated with the use of oral penicillins and cephalosporins. Med Clin North Am. 1983;67(1):113-129.

34. Seltsam A, Salama A. Ceftriaxone-induced immune haemolysis: two case reports and a concise review of the literature. Intensive Care Med. 2000;26(9):1390-1394.

35. Bechtold H, Andrassy K, Jahnchen E, et al. Evidence for impaired hepatic vitamin K1 metabolism in patients treated with N-methyl-thiotetrazole cephalosporins. Thromb Haemost. 1984;51:358-361.

36. McCue JD, Gal P, Pearson RC. Interference of new penicillins and cephalosporins with urine glucose monitoring tests. Diabetes Care. 1983;6(5):504-505.

37. Fulton B, Moore LL. Antiinfectives in breastmilk. Part I: penicillins and cephalosporins. J Hum Lact. 1992;8(3):157-158.

38. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108(3):776-789.

39. Kahan JS, Kahan FM, Goegleman R, et al. Thienamycin, a new beta-lactam antibiotic. I: discovery, taxonomy, isolation and physical properties. J Antibiot. 1979;32(1):1-12.

40. Rybak MJ. Resistance to antimicrobial agents: an update. Pharmacotherapy. 2004;24(12 pt 2):203S-215S.

41. Jones RN. Review of the in vitro spectrum of activity of imipenem. Am J Med. 1985;78(6A):22-32.

42. Drusano GL, Standiford HC. Pharmacokinetic profile of imipenem/cilastatin in normal volunteers. Am J Med. 1985;78(6A):47-53.

43. Andes DR, Craig WA. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect Dis Clin North Am. 1999;13(3):595-618.

44. Leroy A, Fillastre JP, Borsa-Lebas F, et al. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Antimicrob Agents Chemother. 1992;36(12):2794-2798.

45. Seto AH, Song JC, Guest SS. Ertapenem-associated seizures in a peritoneal dialysis patient. Ann Pharmacother. 2005;39(2):352-356.

46. Nacarkucuk E, Saglam H, Okan M. Meropenem decreases serum level of valproic acid. Pediatr Neurol. 2004;31(3):232-234.

47. Merrem IV [package insert]. Wilmington, DE: AstraZeneca; 2006.

48. Primaxin IM [package insert]. West Point, PA: Merck & Co.; 1985, 1998.

49. Odio CM, Puig JR, Feris JM, et al. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime in bacterial meningitis in children. Meropenem Meningitis Study Group. Pediatr Infect Dis J. 1999;18(7):581-590.

50. Ennis DM, Cobbs CG. The newer cephalosporins: aztreonam and imipenem. Infect Dis Clin North Am. 1995(3):687-713.

51. Duma RJ, Berry AJ, Smith SM, et al. Penetration of aztreonam into cerebrospinal fluid of patients with and without inflamed meninges. Antimicrob Agents Chemother. 1984;26(5):730-733.

52. Sattler FR, Schramm M, Swabb EA. Safety of aztreonam and SQ 26992 in elderly patients with renal insufficiency. Rev Infect Dis. 1985;7(suppl 4):S622-S627.

53. Fillastre JP, Leroy A, Baudoin C, et al. Pharmacokinetics of aztreonam in patients with chronic renal failure. Clin Pharmacokinet. 1985;10(1):91-100.

54. Alvan G, Nord CE. Adverse effects of monobactams and carbapenems. Drug Saf. 1995;12(5);305-313.

55. Perez Pimiento A, Gomez Martinez M, Minguez Mena A, Trampal Gonzalez A, De Paz Arranz S, Rodriguez Mosquera M. Aztreonam and ceftazidime: evidence of in vivo cross-allergenicity. Allergy. 1998;53(6):624-625.

56. Azactam [package insert]. Princeton, NJ: Bristol-Myers Squibb Co.; 2007.

57. Azactam [package insert]. Princeton, NJ: Bristol-Myers Squibb Co.; 2004.

58. Bosso JA, Black PG. Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis. Pediatr Infect Dis J. 1988;7(3):171-176.

59. Moellering RC Jr. In vitro antibacterial activity of the aminoglycoside antibiotics. Rev Infect Dis. 1983;5(Suppl):S212-S232.

60. Kotra LP, Haddad J, Mobashery S. Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob Agents Chemother. 2000;44(12):3249-3256.

61. Gordon S, Swenson JM, Hill BC, et al. Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. Enterococcal Study Group. J Clin Microbiol. 1992;30(9):2373-2378.

62. Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med. 1993;328(24):1740-1746.

63. Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin North Am. 2003;17(3):503-528.

64. Appel GB. Aminoglycoside nephrotoxicity. Am J Med. 1990;88(suppl 3C):S16-S20; discussion 38S-42S.

65. Lietman PS. Liver disease, aminoglycoside antibiotics and renal dysfunction. Hepatology. 1988;8(4):966-968.

66. Pandya A, Xia X, Radnaabazar J, et al. Mutation in the mitochondrial 12S rRNA gene in two families from Mongolia with matrilineal aminoglycoside ototoxicity. J Med Genet. 1997;34(2):169-172.

67. Hokkanen E. The aggravating effect of some antibiotics on the neuromuscular blockade in myasthenia gravis. Acta Neurol Scand. 1964;40:346-352.

68. Streptomycin Sulfate [package insert]. New York, NY: Pfizer Inc.; 1998.

69. Alkadi HO, Nooman MA, Raja'a YA. Effect of gentamicin on serum digoxin level in patients with congestive heart failure.Pharm World Sci. 2004;26(2):107-109.

70. Tobramycin Solution for Inhalation [package insert]. Seattle, WA: Pathogenesis Corp.; 1998.

71. Dashe JS, Gilstrap LC III. Antibiotic use in pregnancy. Obstet Gynecol Clin North Am. 1997;24(3):617-629.

72. Goldman RC, Fesik SW, Doran CC. Role of protonated and neutral forms of macrolides in binding to ribosomes from gram-positive and gram-negative bacteria. Antimicrob Agents Chemother. 1990;34(3):426-431.

73. File TM. Telithromycin new product overview. J Allergy Clin Immunol. 2005;115(2):S1-S13.

74. Sun H, Maglio D, Nicolau D. Macrolide resistance in Streptococcus pneumoniae: mechanisms, patterns, and clinical implications of resistance. Conn Med. 2004;68(9):571-576.

75. Matsuoka M, Sasaki T. Inactivation of macrolides by producers and pathogens. Curr Drug Targets Infect Disord. 2004;4(3):217-240.

76. Doern GV, Jorgensen JH, Thornsberry C, et al. National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae. Antimicrob Agents Chemother. 1988;32(2):180-185.

77. Malmborg AS. Effect of food on absorption of erythromycin: a study of two derivatives, the stearate and the base. J Amtimicrob Chemother. 1979;5(5):591-599.

78. Bahal N, Nahata MC. The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother. 1992;26(1):46-55.

79. Periti P, Mazzei T, Mini E, Novelli A. Clinical pharmacokinetic properties of the macrolide antibiotics: effects of age and various pathophysiological states (Part II). Clin Pharmacokinet. 1989;16(5):261-282.

80. Zuckerman JM. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am. 2004;18(3): 621-649.

81. Clark JP, Langston E. Ketolides: a new class of antibacterial agents for treatment of community-acquired respiratory tract infections in a primary care setting. Mayo Clin Proc. 2003;78(9):1113-1124.

82. Katapadik K, Kostandy G, Katapadi M, et al. A review of erythromycin-induced malignant tachyarrhythmia—torsade de pointes: a case report. Angiology. 1997;48:821-826.

83. Guay DR, Patterson DR, Seipman N, Craft JC. Overview of the tolerability profile of clarithromycin in preclinical and clinical trials. Drug Saf. 1993;8(5):350-364.

84. Wellington K, Noble S. Telithromycin. Drugs. 2004;64(15):1683-1694.

85. Ludden TM. Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet. 1985;10:63-79.

86. Kahri AJ, Valkonen MM, Vuoristo MK, Pentikainen PJ. Rhabdomyolysis associated with concomitant use of simvastatin and clarithromycin. Ann Pharmacother. 2004;38(4):719.

87. Desta Z, Soukhova N, Flockhart DA. In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors and azithromycin. J Clin Psychopharmacol. 2002;22(2):162-168.

88. Watkins VS, Polk RE, Stotka JL. Drug interactions of macrolides: emphasis on dirithromycin. Ann Pharmacother. 1997;31(3): 349-356.

89. Kolilekas L, Anagnostopoulos GK, Lampaditis I, Eleftheriadis I. Potential interaction between telithromycin and warfarin.Ann Pharmacother. 2004;38(9):1424-1427.

90. Centers for Disease Control and Prevention. Chlamydia trachomatis infections: policy guidelines for prevention and control. MMWR. 1985;34(3-S):S53-S74.

91. Kacmar J, Cheh E, Montagno A, Peipert JF. A randomized trial of azithromycin versus amoxicillin for the treatment of Chlamydia trachomatis in pregnancy. Infect Dis Obstet Gynecol. 2001;9(4):197-202.

92. Drinkard CR, Shatin D, Clouse J. Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations. Pharmacoepidemiol Drug Saf. 2000;9(7):549-556.

93. Einarson A, Phillips E, Mawji F, et al. A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol. 1998;15(9):523-525.

94. Hauben M, Amsden GW. The association of erythromycin and infantile hypertrophic pyloric stenosis: causal or coincidental?Drug Saf. 2002;25(13):929-942.

95. Andersson MI, MacGowan AP. Development of the quinolones. J Antimicrob Chemother. 2003;51(Suppl 1):1-11.

96. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol. Biol R. 1997;61(3):377-392.

97. Willmott CJ, Maxwell A. A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antimicrob Agents Chemother. 1993;37:126-127.

98. Mammeri H, Van De Loo M, Poirel L, Martinez-Martinez l, Nordmann P. Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob Agents Chemother. 2005;49(1):71-76.

99. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. J Antimicrob Chemother. 1999;43(suppl B):1-11.

100. Sorgel F, Kinzig M. Pharmacokinetics of gyrase inhibitors, part 1: basic chemistry and gastrointestinal disposition. Am J Med. 1993;94(3A):S44-S55.

101. Sorgel F, Kinzig M. Pharmacokinetics of gyrase inhibitors, part 2: renal and hepatic elimination pathways and drug interactions.Am J Med. 1993; 94(3A):S56-S69.

102. Moise PA, Birmingham MC, Schentag JJ. Pharmacokinetics and metabolism of moxifloxacin. Drugs Today. 2000;36(4):229-244.

103. Fillastre JP, Leroy A, Moulin B, Dhib M, Borsa-Lebas F, Humbert G. Pharmacokinetics of quinolones in renal insufficiency.J Antimicrob Chemother. 1990;26(suppl B):51-60.

104. Cohen JS. Peripheral neuropathy associated with fluoroquinolones. Ann Pharmacother. 2001;35(12):1540-1547.

105. Zabraniecki L, Negrier I, Vergne P, et al. Fluoroquinolone induced tendinopathy: report of 6 cases. J Rheumatol. 1996;23(3): 516-520.

106. Oh YR, Carr-Lopez SM, Probasco JM, Crawley PG. Levofloxacin-induced autoimmune hemolytic anemia. Ann Pharmacother. 2003;37(7-8):1010-1013.

107. Coleman CI, Spencer JV, Chung JO, Reddy P. Possible gatifloxacin-induced fulminant hepatic failure. Ann Pharmacother. 2002;36(7-8):1162-1167.

108. Lin G, Hays DP, Spillane L. Refractory hypoglycemia from ciprofloxacin and glyburide interaction. J Toxicol Clin Toxicol. 2004;42(3):295-297.

109. Polk RE, Healy DP, Sahai J, Drwal L, Racht E. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother. 1989;33(11):1841-1844.

110. Hori S, Kizu J, Kawamura M. Effects of anti-inflammatory drugs on convulsant activity of quinolones: a comparative study of drug interaction between quinolones and anti-inflammatory drugs. J Infect Chemother. 2003;9(4):314-320.

111. Radandt JM, Marchbanks CR, Dudley MN. Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clin Infect Dis. 1992;14(1):272-284.

112. Von Keutz E, Ruhl-Fehlert C, Drommer W, Rosenbruch M. Effects of ciprofloxacin on joint cartilage in immature dogs immediately after dosing and after a 5-month treatment-free period. Arch Toxicol. 2004;78(7):418-424.

113. Grady R. Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J. 2003;22(12):1128-1132.

114. Redmond A, Sweeney L, MacFarland M, Mitchell M, Daggett S, Kubin R. Oral ciprofloxacin in the treatment of Pseudomonas exacerbations of paediatric cystic fibrosis: clinical efficacy and safety evaluation using magnetic resonance image scanning.J Int Med Res. 1998;26(6):304-312.

115. Woods DD. Relation of p-aminobenzoic acid to mechanism of action of sulphanilamide. Br J Exp Pathol. 1940;21:74-90.

116. Radstrom P, Fermer C, Kristiansen BE, Jenkins A, Skold O, Swedberg G. Transformational exchanges in the dihydropteroate synthetase gene of Neisseria meningitidis: a novel mechanism for acquisition of sulfonamide resistance. J Bacteriol. 1992;174(20):6386-6393.

117. Then RL. Mechanisms of resistance to trimethoprim, the sulfonamides and trimethoprim-sulfamethoxazole. Rev Infect Dis. 1982;4(2):261-269.

118. Bushby SRM. Trimethoprim-sulfamethoxazole: in vitro microbiologic aspects. J Infect Dis. 1973;128(suppl):442-462.

119. Houvinen P. Trimethoprim resistance. Antimicrob Agents Chemother. 1987;31(10):1451-1456.

120. Hekster CA, Vree TB. Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives. Antibiot Chemother. 1982;31:118-122.

121. Foltzer MA, Reese RE. Trimethoprim-sulfamethoxazole and other sulfonamides. Med Clin North Am. 1987;71(6):1177-1194.

122. Lawson DH, Paice BJ. Adverse reactions to trimethoprim-sulfamethoxazole. Rev Infect Dis. 1982;4(2):429-433.

123. Keisu M, Wiholm BE, Palmblad J. Trimethoprim-sulphamethoxazole-associated blood dyscrasias: ten years' experience of the Swedish spontaneous reporting system. J Intern Med. 1990;228(4):353-360.

124. Markowitz N, Saravolatz LD. Use of trimethoprim-sulfamethoxazole in a glucose-6-phosphate dehydrogenase-deficient population. Rev Infect Dis. 1987;9:S218-S229.

125. Kaufman JM, Fauver HE Jr. Potentiation of warfarin by trimethoprim-sulfamethoxazole. Urology. 1980;16(6):601-603.

126. Campana C, Regazzi MB, Buggia I, Molinaro M. Clinically significant drug interactions with cyclosporine: an update. Clin Pharmacokinet. 1996;30(2):141-179.

127. Springer C, Eyal F, Michael J. Pharmacology of trimethoprim-sulfamethoxazole in newborn infants. J Pediatr. 1982;100(4):647-650.

128. Silvadene Cream [package insert]. Bristol, TN: King Pharmaceuticals; 2003.

129. Craven GR, Gavin R, Fanning T. The transfer RNA binding site of the 30 S ribosome and the site of tetracycline inhibition.Cold Spring Symp Quant Biol. 1969;34:129-137.

130. Schnappinger D, Hillen W. Tetracyclines: antibiotic action, uptake, and resistance mechanisms. Arch Microbiol. 1996;165(6): 359-369.

131. Speer BS, Shoemaker NB, Salyers AA. Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance.Clin Microbiol Rev. 1992;5(4):387-399.

132. Forrest JN, Cox M, Hong C, Morrison G, Bia M, Singer I. Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med. 1978;298(4):173-177.

133. Karlsson M, Hammers S, Nilsson-Ehle I, Malmborg AS, Wretlind B. Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis. Antimicrob Agents Chemother. 1996;40(5):1104-1107.

134. Yim CW, Flynn NM, Fitzgerald FT. Penetration of oral doxycycline into the cerebrospinal fluid of patients with latent or neurosyphilis. Antimicrob Agents Chemother. 1985;28(2):347-348.

135. Forti G, Benincori C. Doxycycline and the teeth. Lancet. 1969;1(7598):782.

136. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet. 1988;15(6):355-366.

137. Houin G, Brunner F, Nebout T, Chereaoui M, Lagrue G, Tillement JP. The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man. Br J Clin Pharmacol. 1983;16(3):245-252.

138. Vial T, Biour M, Descotes J, Trepo C. Antibiotic-associated hepatitis: update from 1990. Ann Pharmacother. 1997;31(2):204-220.

139. Angeloni VL, Salasche SJ, Ortiz R. Nail, skin, and scleral pigmentation induced by minocycline. Cutis. 1987;40(3):229-233.

140. Byrne PA, Williams BD, Pritchard MH. Minocycline-related lupus. Br J Rheumatol. 1994;33:674-676.

141. Gugler R, Allgayer H. Effects of antacids on the clinical pharmacokinetics of drugs: an update. Clin Pharmacokinet. 1990;18(3): 210-219.

142. Bacon JF, Shenfield GM. Pregnancy attributable to interaction between tetracycline and oral contraceptives. Br Med J. 1980;280(6210):293.

143. Dickinson BD, Altman RD, Nielsen NH, Sterling ML, Council on Scientific Affairs, American Medical Association. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol. 2001;98(5 pt 1):853-860.

144. Danos EA. Apparent potentiation of warfarin activity by tetracycline. Clin Pharm. 1992;11(9):806-808.

145. Rodin SM, Johnson BF. Pharmacokinetic interactions with digoxin. Clin Pharmacokinet. 1988;15(4):227-244.

146. Frost HM. Tetracyclines and fetal bones. Henry Ford Hosp Med J. 1965;13(4):403-410.

147. Allen ES, Brown WE. Hepatic toxicity of tetracycline in pregnancy. Am J Obstet Gynecol. 1966;95(1):12-18.

148. 148. Mosby's Drug Consult 2007. 17th edition. St. Louis, MO; Mosby, Inc; 2006.

149. Lexicomp Online. Available at http://online.lexi.com. Last accessed January 11, 2018.

150. Allchin D. Penicillin and Chance. Available at http://shipseducation.net/sacredbovines/SB-Penicillin-chance.htm. Last accessed January 3, 2018.

151. Hwa-Froelich DA, Westby CE. Considerations when working with interpreters. Communication Disorders Quarterly. 2003;4(2): 78-85.

152. Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2011;52(9):1156-1163.

153. File TM Jr, Wilkoz MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis. 2012;55(suppl 3): S173-S180.

154. Low DE, File TM Jr, Eckburg PB, et al. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl 3):iii33-iii44.

155. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA Requires Label Changes to Warn of Risk for Possibly Permanent Nerve Damage from Antibacterial Fluoroquinolone Drugs Taken by Mouth or by Injection. Available at http://www.fda.gov/downloads/Drugs/DrugSafety/UCM365078.pdf. Last accessed January 10, 2018.

156. Reynolds PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis. 1989;8(11):943-950.

157. Rybak MJ, Lomaestro BM, Rotachafer JC, et al. Therapeutic monitoring of vancomycin in adults: summary of consensus recommendations for the American Society of Health-System Pharmacists, the Infectious Disease Society of America, and the Society of Infectious Disease Pharmacists. Pharmacotherapy. 2009;29:1275-1279.

158. Mergenhagen KA, Borton AR. Vancomycin nephrotoxicity: a review. J Pharm Pract. 2014;27(6):545-553.

159. Guskey MT, Tsuji BT. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy. 2010;30:80-94.

160. Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010;70(7):859-886.

161. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169-2179.

162. Bradley JS, Puttagunta S, Rubino CM, Blumer JL, Dunne M, Sullivan JE. Pharmacokinetics, safety, and tolerability of single dose dalbavancin in children 12 through 17 years of age. Pediatr Infect Dis J. 2015;34(7):748-752.

163. U.S. Food and Drug Administration. FDA Approves New Antibacterial Drug. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573955.htm. Last accessed January 9, 2018.

164. Centers for Disease Control and Prevention. Antibiotic/Antimicrobial Resistance. Available at https://www.cdc.gov/drugresistance/index.html. Last accessed January 3, 2018.

165. Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in the United States: an investigation into its epidemiology. Arch Intern Med. 2001;161(1):15–21.

166. Herbert ME, Brewster GS, Lanctot-Herbert M. Ten percent of patients who are allergic to penicillin will have serious reactions if exposed to cephalosporins. Western Journal of Medicine. 2000;172(5):341.

167. Bhattacharya S. The facts about penicillin allergy: a review. J Adv Pharm Technol Res. 2010;1(1):11-17.

168. American College of Allergy, Asthma, and Immunology. Penicillin Allergy: Facts for Patients. Available at http://college.acaai.org/sites/default/files/Patient%20factsheet.%20Penicillin%20allergy.%20Facts%20for%20patients.pdf. Last accessed January 4, 2018.

169. Spasovski G, Vanholder R, Allolio B, et al. Hyponatraemia guideline development group: clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol. 2014;170(3):G1-G47.

170. United States Food and Drug Administration. Intraocular Injections of a Compounded Triamcinolone, Moxifloxacin, and Vancomycin (TMV) Formulation: FDA Statement - Case of Hemorrhagic Occlusive Retinal Vasculitis. Available at https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm578743.htm. Last accessed January 9, 2018.

171. Crotty MP, Krekel T, Burnham C-AD, Ritchie DJ. New Gram-positive agents: the next generation of oxazolidinones and lipoglycopeptides. J Clin Microbiol. 2016;54:2225-2232.

172. Parmar A, Iyer A, Vincent CS, et al. Efficient total syntheses and biological activities of two teixobactin analogues. Chem Commun. 2016;52:6060-6063.

173. Ling LL, Schneider T, Peoples AJ, et al. A new antibiotic kills pathogens without detectable resistance. Nature. 2015;517:455-459.

174. Maffioli SI, Zhang Y, Degen D, et al. Antibacterial nucleoside-analog inhibitor of bacterial RNA polymerase. 2017;169(7):1240-1248.

175. American Association for the Advancement of Science. Researchers Discover New Antibiotic Effective Against Drug-Resistant Bacteria. Available at https://www.eurekalert.org/pub_releases/2017-06/ru-rdn060817.php. Last accessed January 10, 2018.

176. U.S. Food and Drug Administration. FDA Updates Warnings for Fluoroquinolone Antibiotics on Risks of Mental Health and Low Blood Sugar Adverse Reactions. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm612995.htm. Last accessed July 12, 2018.

Evidence-Based Practice Recommendations Citations

1. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431-455. Available at https://www.cdc.gov/HAI/pdfs/cdiff/Cohen-IDSA-SHEA-CDI-guidelines-2010.pdf. Last accessed January 22, 2018.

2. Davey P, Marwick CA, Scott CL, et al. Improving how physicians working in hospital settings prescribe antibiotics. Cochrane Database System Rev. 2017;(4):CD003543. Available at http://www.cochrane.org/CD003543/EPOC_improving-how-physicians-working-hospital-settings-prescribe-antibiotics. Last accessed January 22, 2018.

3. American Optometric Association. Care of the Patient with Ocular Surface Disorders. St. Louis, MO: American Optometric Association; 2010. Available at https://www.aoa.org/documents/optometrists/CPG-10.pdf. Last accessed January 22, 2018.



Privacy Policy
Copyright © 2018 CE Resource, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.